Cargando…

Plasma cell-free DNA integrity: a potential biomarker to monitor the response of breast cancer to neoadjuvant chemotherapy

BACKGROUND: Although the clinical significance of neoadjuvant chemotherapy (NACT) is widely recognized, there is still no effective means to monitor the therapeutic response in real time. The present study aimed to investigate the significance of the cell-free DNA (cfDNA) concentration and integrity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wei, Zhang, Weijie, Su, Lei, Sang, Jianfeng, Wang, Shui, Yao, Yongzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799030/ https://www.ncbi.nlm.nih.gov/pubmed/35116896 http://dx.doi.org/10.21037/tcr.2019.08.05

Ejemplares similares

Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy
por: Zhu, Feng, et al.
Publicado: (2021)

Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer
por: Ma, Ge, et al.
Publicado: (2020)

Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
por: Cirmena, Gabriella, et al.
Publicado: (2022)

Plasma Cell-Free DNA as a Novel Biomarker for the Diagnosis and Monitoring of Atherosclerosis
por: Qian, Benheng, et al.
Publicado: (2022)

Monitoring early responses to neoadjuvant chemotherapy and the factors affecting neoadjuvant chemotherapy responses in primary osteosarcoma
por: Yu, Hong, et al.
Publicado: (2023)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma
por: Su, Yan, et al.
Publicado: (2019)

Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter
por: Piotrzkowska-Wróblewska, Hanna, et al.
Publicado: (2019)

Association between the nucleosome footprint of plasma DNA and neoadjuvant chemotherapy response for breast cancer
por: Yang, Xu, et al.
Publicado: (2021)

Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
por: Christensen, Emil, et al.
Publicado: (2023)

Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA)
por: Patsch, Katherin, et al.
Publicado: (2019)

The Plasma Concentration of D-Dimer is Associated with Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma
por: Huang, Yujing, et al.
Publicado: (2021)

DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis
por: Vici, Patrizia, et al.
Publicado: (2016)

Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience
por: Meaney, Paul M, et al.
Publicado: (2013)

Dedicated Breast CT: Feasibility for Monitoring Neoadjuvant Chemotherapy Treatment
por: Vedantham, Srinivasan, et al.
Publicado: (2014)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma
por: Eskander, Nancy Samir, et al.
Publicado: (2022)

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Meyer, Braydon, et al.
Publicado: (2021)

Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
por: Zarotti, Cristina, et al.
Publicado: (2022)

Effectiveness and Safety of Zercepac and Reference Trastuzumab in the Neoadjuvant Setting for Early-Stage Breast Cancer: A Retrospective Cohort Study
por: Liu, Zheying, et al.
Publicado: (2022)

Plasma cfDNA as a Potential Biomarker to Evaluate the Efficacy of Chemotherapy in Gastric Cancer
por: Zhong, Yuejiao, et al.
Publicado: (2020)

Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy
por: Sakaguchi, Asumi, et al.
Publicado: (2021)

Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma
por: Huang, Ao, et al.
Publicado: (2016)

Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy
por: Busch, David R., et al.
Publicado: (2012)

Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
por: Nolen, Brian M, et al.
Publicado: (2008)

FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction
por: Liu, Shuo, et al.
Publicado: (2020)

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Lin, Huaqin, et al.
Publicado: (2021)

Prognostic Value of Plasma Epstein-Barr Virus DNA Levels Pre- and Post-Neoadjuvant Chemotherapy in Patients With Nasopharyngeal Carcinoma
por: Zhu, Lisheng, et al.
Publicado: (2021)

Early assessment of circulating exosomal lncRNA-GC1 for monitoring neoadjuvant chemotherapy response in gastric cancer
por: Guo, Xin, et al.
Publicado: (2023)

Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy
por: Khandakar, Binny, et al.
Publicado: (2014)

Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer
por: Zhang, Meng, et al.
Publicado: (2023)

Fully integrated wearable humidity sensor for respiration monitoring
por: Jin, Xiaofeng, et al.
Publicado: (2022)

Thermal tomography for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer
por: Wu, Qi, et al.
Publicado: (2017)

Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer
por: Gan, Xuejun, et al.
Publicado: (2023)

Plasma cell-free DNA promise monitoring and tissue injury assessment of COVID-19
por: Jin, Xin, et al.
Publicado: (2023)

Monitoring Breast Cancer Response to Neoadjuvant Chemotherapy Using Ultrasound Strain Elastography
por: Fernandes, Jason, et al.
Publicado: (2019)

Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer
por: Yang, Gaohua, et al.
Publicado: (2022)

Dynamic monitoring of CD45-/CD31+/DAPI+ circulating endothelial cells aneuploid for chromosome 8 during neoadjuvant chemotherapy in locally advanced breast cancer
por: Ma, Ge, et al.
Publicado: (2020)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Neoadjuvant chemotherapy for upper tract urothelial carcinoma
por: Kim, Do Kyung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4ui7sua2bb096hh7p9l63ka1jv